ArticleBMJ open2013
Would primary healthcare professionals prescribe a polypill to manage cardiovascular risk? A qualitative interview study.
Article in BMJ open, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Pooled it
- Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases.The Cochrane database of systematic reviews · 2017Pooled it
- Fixed-dose combination therapy for the prevention of cardiovascular disease.The Cochrane database of systematic reviews · 2014Pooled it
- Process Evaluation of a Double-Blind Randomized Controlled Trial to Assess the Efficacy and Safety of a Quadruple Ultra-Low-Dose Treatment for Hypertension Within a Federally Qualified Health Center Network (QUARTET USA).Journal of the American Heart Association · 2024Trial
- Provider Preferences About a Polypill for Heart Failure With Reduced Ejection Fraction: Development of a Multicenter Physician Survey Containing a Discrete Choice Experiment.Journal of cardiac failure - intersections · 2026Article
- Polypill Strategies for Cardiovascular Prevention in Older Adults: Evidence, Opportunities, and Implementation Challenges.Drugs & aging · 2025Review
- WHF Roadmap on Single Pill Combination Therapies.Global heart · 2025Review
- The Polypill: A New Alternative in the Prevention and Treatment of Cardiovascular Disease.Journal of clinical medicine · 2024Review
- A Cross-Sectional Survey of Fixed-Dose Combination Antihypertensive Medicine Prescribing in Twenty-Four Countries, Including Qualitative Insights.Global heart · 2024Article
- Frontiers of cardiovascular polypills: From atherosclerosis and beyond.Trends in cardiovascular medicine · 2023Review
- Implementation of fixed-dose combination therapy for secondary prevention of atherosclerotic cardiovascular disease among Syrian refugees in Lebanon: a qualitative evaluation.BMC health services research · 2022Article
- The Attitude towards Polypills Questionnaire (APPQ): a phase I-III development and validation study in patients with cerebrovascular disease.European journal of neurology · 2021Article
- Article
- Fixed-Dose Combination Medications for Treating Hypertension: A Review of Effectiveness, Safety, and Challenges.Current hypertension reports · 2020Review
- Article
- Usefulness of the Polypill for the Prevention of Cardiovascular Disease and Hypertension.Current hypertension reports · 2016Review
- Polypill: Progress and Challenges to Global Use--Update on the Trials and Policy Implementation.Current cardiology reports · 2015Review
- Patients' views about taking a polypill to manage cardiovascular risk: a qualitative study in primary care.The British journal of general practice : the journal of the Royal College of General Practitioners · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
objectivesA 'polypill' containing both blood pressure-lowering and cholesterol-lowering drugs could prevent up to 80% of cardiovascular disease events. Since little is known about the attitudes of primary healthcare professionals to use of such a pill for cardiovascular disease prevention, this study aimed to investigate opinions.
designSemistructured interviews were conducted with participants. A qualitative description approach was used to analyse and report the results.
settingParticipants were recruited from nine primary care practices in Birmingham.
participantsSixteen healthcare professionals (11 primary care physicians and 5 practice nurses) were selected through purposive sampling to maximise variation of characteristics. OUTCOME MEASURES: Outcome measures for this study were: the attitude of healthcare professionals towards the use of a polypill for primary and secondary cardiovascular disease prevention; their views on monitoring the drug; and the factors influencing their willingness to prescribe the medication.
resultsHealthcare professionals expressed considerable concern over using a polypill for primary prevention for all people over a specific age, although there was greater acceptance of its use for secondary prevention. Regularly monitoring patients taking the polypill was deemed essential. Evidence of effectiveness, patient risk level and potential medicalisation were key determinants in willingness to prescribe such a pill.
conclusionsPrimary healthcare professionals have significant concerns about the use of a polypill, particularly in the prevention of cardiovascular disease in people who are not regarded as being at 'high risk'. If a population-based polypill strategy is to be successfully implemented, healthcare professionals will need to be convinced of the potential benefits of a drug-based population approach to prevention.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.